For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Race Oncology has been given ethics approval for a Phase I trial of RC220 bisantrene alone and in combination with ... Read ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Cryotherapy is emerging as a promising strategy to prevent chemotherapy-induced peripheral neuropathy, but adoption in clinical practice remains limited.

Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...

Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

The company will publish its Full-Year 2024 financial results on March 26, 2025. On the reporting date, BioVersys will issue a press release at 7:00 AM CET.

RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities ...